Home › Companies › PUMA BIOTECHNOLOGY INC. › 2024-2025

PUMA BIOTECHNOLOGY INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and PUMA BIOTECHNOLOGY INC.’s Form 8-K, filed June 13, 2025 (Item 5.07 on EDGAR). Page generated October 25, 2026.

10Ballot items
148Asset managers
1,532Fund votes
June 11, 2025Meeting date

Results at a glance

Meeting of June 11, 2025: 10 items on PUMA BIOTECHNOLOGY INC.’s Form 8-K, filed June 13, 2025: 2 approved · 8 without a stated outcome.

Material dissent

Elect Director: Alessandra Cesano 74% of votes cast Outcome not stated Director under 80%
Elect Director: Troy E. Wilson 69% of votes cast Outcome not stated Director under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2024-2025 2025-2026

Explore PUMA BIOTECHNOLOGY INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by PUMA BIOTECHNOLOGY INC.

These tallies are PUMA BIOTECHNOLOGY INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 13, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

PUMA BIOTECHNOLOGY INC. — official shareholder meeting results, meeting held June 11, 2025
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Alan H. Auerbach	34,639,223	--	--	408,312	6,521,146	99%	Not verified	—
Elect Director: Alessandra Cesano	26,100,362	--	--	8,947,173	6,521,146	74%	Not verified	—
Elect Director: Allison Dorval	34,757,965	--	--	289,570	6,521,146	99.1%	Not verified	—
Elect Director: Michael P. Miller	34,501,336	--	--	546,199	6,521,146	98%	Not verified	—
Elect Director: Jay M. Moyes	34,453,681	--	--	593,854	6,521,146	98%	Not verified	—
Elect Director: Adrian M. Senderowicz	34,504,501	--	--	543,034	6,521,146	98%	Not verified	—
Elect Director: Brian Stuglik	34,742,184	--	--	305,351	6,521,146	99.1%	Not verified	—
Elect Director: Troy E. Wilson	24,308,330	--	--	10,739,205	6,521,146	69%	Not verified	—
2. The selection of KPMG LLP as the Company's independent registered accounting firm for the fiscal year ending December 31, 2025	40,683,257	739,693	145,731	--	0	98%	Approved	—
Proposal 3: The Company's stockholders voted to approve, on an advisory basis, the compensation of the Company's named executive officers.	32,617,895	1,698,665	730,975	--	6,521,146	95%	Approved	—

Source: PUMA BIOTECHNOLOGY INC., Form 8-K, filed with the SEC on June 13, 2025 — read the filing on EDGAR.

How asset managers voted at the PUMA BIOTECHNOLOGY INC. 2024-2025 meeting

Each item below shows how the 148 asset managers that disclosed a PUMA BIOTECHNOLOGY INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Adrian M. Senderowicz

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 34,504,501WITHHELD: 543,034

Details: description as filed, official tally, votes by 55 asset managers

Description as filed by funds: Election of directors to serve for a one-year term: Adrian M. Senderowicz

PUMA BIOTECHNOLOGY INC.’s own tally for this item (“Elect Director: Adrian M. Senderowicz”): 34,504,501 for, 543,034 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 10,112,240 for, 14,244 withheld, 105,823 abstained.

FOR

FOR: 10,112,240ABSTAIN: 105,823WITHHOLD: 14,244

Largest asset managers voting on “Election of directors to serve for a one-year term: Adrian M. Senderowicz” at PUMA BIOTECHNOLOGY INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	3,722,520	0	For
BlackRock	1,813,759	0	For
American Century	1,176,354	0	For
Fidelity	1,059,127	0	For
Dimensional	410,482	0	For
SEI	328,839	0	For
TARGET PORTFOLIO TRUST	276,200	0	For
Federated Hermes	193,766	0	For
BRIDGEWAY FUNDS INC	141,300	0	For
Charles Schwab	127,312	0	For
WisdomTree	83,143	0	For
Equitable	81,633	0	For
RBC FUNDS TRUST	0	71,800	Abstain
QUANTITATIVE MASTER SERIES LLC	67,080	0	For
Delaware/Macquarie	61,255	0	For
TIAA	55,922	0	For
GPS Funds I	43,280	0	For
Virtus	41,614	0	For
Goldman Sachs	40,114	0	For
Pacific Life	35,848	0	For
EA Series Trust	0	34,023	Abstain
Lincoln Financial	32,878	0	For
Legg Mason	32,690	0	For
Putnam	31,246	0	For
Exchange Place Advisors Trust	27,546	0	For

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

2. Elect Director: Alan H. Auerbach

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 34,639,223WITHHELD: 408,312

Details: description as filed, official tally, votes by 55 asset managers

Description as filed by funds: Election of directors to serve for a one-year term: Alan H. Auerbach

PUMA BIOTECHNOLOGY INC.’s own tally for this item (“Elect Director: Alan H. Auerbach”): 34,639,223 for, 408,312 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 10,218,063 for, 14,244 withheld.

FOR

FOR: 10,218,063WITHHOLD: 14,244

Largest asset managers voting on “Election of directors to serve for a one-year term: Alan H. Auerbach” at PUMA BIOTECHNOLOGY INC., 2024-2025
Asset manager	For	Vote
Vanguard	3,722,520	For
BlackRock	1,813,759	For
American Century	1,176,354	For
Fidelity	1,059,127	For
Dimensional	410,482	For
SEI	328,839	For
TARGET PORTFOLIO TRUST	276,200	For
Federated Hermes	193,766	For
BRIDGEWAY FUNDS INC	141,300	For
Charles Schwab	127,312	For
WisdomTree	83,143	For
Equitable	81,633	For
RBC FUNDS TRUST	71,800	For
QUANTITATIVE MASTER SERIES LLC	67,080	For
Delaware/Macquarie	61,255	For
TIAA	55,922	For
GPS Funds I	43,280	For
Virtus	41,614	For
Goldman Sachs	40,114	For
Pacific Life	35,848	For
EA Series Trust	34,023	For
Lincoln Financial	32,878	For
Legg Mason	32,690	For
Putnam	31,246	For
Exchange Place Advisors Trust	27,546	For

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

3. Elect Director: Alessandra Cesano

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD

FOR: 26,100,362WITHHELD: 8,947,173

Details: description as filed, official tally, votes by 55 asset managers

Description as filed by funds: Election of directors to serve for a one-year term: Alessandra Cesano

PUMA BIOTECHNOLOGY INC.’s own tally for this item (“Elect Director: Alessandra Cesano”): 26,100,362 for, 8,947,173 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 3,803,989 for, 4,517,627 withheld, 1,910,691 abstained.

FORABSTAINWITHHOLD

FOR: 3,803,989ABSTAIN: 1,910,691WITHHOLD: 4,517,627

Largest asset managers voting on “Election of directors to serve for a one-year term: Alessandra Cesano” at PUMA BIOTECHNOLOGY INC., 2024-2025
Asset manager	For	Abstain	Withheld	Vote
Vanguard	86,986	0	3,635,534	Withhold
BlackRock	0	1,813,759	0	Abstain
American Century	1,176,354	0	0	For
Fidelity	1,059,127	0	0	For
Dimensional	410,482	0	0	For
SEI	0	0	328,839	Withhold
TARGET PORTFOLIO TRUST	0	0	276,200	Withhold
Federated Hermes	193,766	0	0	For
BRIDGEWAY FUNDS INC	141,300	0	0	For
Charles Schwab	0	0	127,312	Withhold
WisdomTree	83,143	0	0	For
Equitable	6,480	0	75,153	Mixed
RBC FUNDS TRUST	71,800	0	0	For
QUANTITATIVE MASTER SERIES LLC	0	67,080	0	Abstain
Delaware/Macquarie	61,255	0	0	For
TIAA	55,922	0	0	For
GPS Funds I	43,280	0	0	For
Virtus	41,614	0	0	For
Goldman Sachs	40,114	0	0	For
Pacific Life	15,714	0	20,134	Mixed
EA Series Trust	34,023	0	0	For
Lincoln Financial	32,878	0	0	For
Legg Mason	32,690	0	0	For
Putnam	31,246	0	0	For
Exchange Place Advisors Trust	27,546	0	0	For

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

4. Elect Director: Allison Dorval

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%

FOR: 34,757,965WITHHELD: 289,570

Details: description as filed, official tally, votes by 55 asset managers

Description as filed by funds: Election of directors to serve for a one-year term: Allison Dorval

PUMA BIOTECHNOLOGY INC.’s own tally for this item (“Elect Director: Allison Dorval”): 34,757,965 for, 289,570 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.1% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 10,222,289 for, 10,018 withheld.

FOR

FOR: 10,222,289WITHHOLD: 10,018

Largest asset managers voting on “Election of directors to serve for a one-year term: Allison Dorval” at PUMA BIOTECHNOLOGY INC., 2024-2025
Asset manager	For	Vote
Vanguard	3,722,520	For
BlackRock	1,813,759	For
American Century	1,176,354	For
Fidelity	1,059,127	For
Dimensional	410,482	For
SEI	328,839	For
TARGET PORTFOLIO TRUST	276,200	For
Federated Hermes	193,766	For
BRIDGEWAY FUNDS INC	141,300	For
Charles Schwab	127,312	For
WisdomTree	83,143	For
Equitable	81,633	For
RBC FUNDS TRUST	71,800	For
QUANTITATIVE MASTER SERIES LLC	67,080	For
Delaware/Macquarie	61,255	For
TIAA	55,922	For
GPS Funds I	43,280	For
Virtus	41,614	For
Goldman Sachs	40,114	For
Pacific Life	35,848	For
EA Series Trust	34,023	For
Lincoln Financial	32,878	For
Legg Mason	32,690	For
Putnam	31,246	For
Exchange Place Advisors Trust	27,546	For

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

5. Elect Director: Brian Stuglik

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%

FOR: 34,742,184WITHHELD: 305,351

Details: description as filed, official tally, votes by 55 asset managers

Description as filed by funds: Election of directors to serve for a one-year term: Brian Stuglik

PUMA BIOTECHNOLOGY INC.’s own tally for this item (“Elect Director: Brian Stuglik”): 34,742,184 for, 305,351 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 55 asset managers below reported 10,222,118 for, 10,189 withheld.

FOR

FOR: 10,222,118WITHHOLD: 10,189

Largest asset managers voting on “Election of directors to serve for a one-year term: Brian Stuglik” at PUMA BIOTECHNOLOGY INC., 2024-2025
Asset manager	For	Vote
Vanguard	3,722,520	For
BlackRock	1,813,759	For
American Century	1,176,354	For
Fidelity	1,059,127	For
Dimensional	410,482	For
SEI	328,839	For
TARGET PORTFOLIO TRUST	276,200	For
Federated Hermes	193,766	For
BRIDGEWAY FUNDS INC	141,300	For
Charles Schwab	127,312	For
WisdomTree	83,143	For
Equitable	81,633	For
RBC FUNDS TRUST	71,800	For
QUANTITATIVE MASTER SERIES LLC	67,080	For
Delaware/Macquarie	61,255	For
TIAA	55,922	For
GPS Funds I	43,280	For
Virtus	41,614	For
Goldman Sachs	40,114	For
Pacific Life	35,848	For
EA Series Trust	34,023	For
Lincoln Financial	32,878	For
Legg Mason	32,690	For
Putnam	31,246	For
Exchange Place Advisors Trust	27,546	For

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

6. Elect Director: Jay M. Moyes

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 34,453,681WITHHELD: 593,854

Details: description as filed, official tally, votes by 55 asset managers

Description as filed by funds: Election of directors to serve for a one-year term: Jay M. Moyes

PUMA BIOTECHNOLOGY INC.’s own tally for this item (“Elect Director: Jay M. Moyes”): 34,453,681 for, 593,854 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 55 asset managers below reported 10,222,118 for, 10,189 withheld.

FOR

FOR: 10,222,118WITHHOLD: 10,189

Largest asset managers voting on “Election of directors to serve for a one-year term: Jay M. Moyes” at PUMA BIOTECHNOLOGY INC., 2024-2025
Asset manager	For	Vote
Vanguard	3,722,520	For
BlackRock	1,813,759	For
American Century	1,176,354	For
Fidelity	1,059,127	For
Dimensional	410,482	For
SEI	328,839	For
TARGET PORTFOLIO TRUST	276,200	For
Federated Hermes	193,766	For
BRIDGEWAY FUNDS INC	141,300	For
Charles Schwab	127,312	For
WisdomTree	83,143	For
Equitable	81,633	For
RBC FUNDS TRUST	71,800	For
QUANTITATIVE MASTER SERIES LLC	67,080	For
Delaware/Macquarie	61,255	For
TIAA	55,922	For
GPS Funds I	43,280	For
Virtus	41,614	For
Goldman Sachs	40,114	For
Pacific Life	35,848	For
EA Series Trust	34,023	For
Lincoln Financial	32,878	For
Legg Mason	32,690	For
Putnam	31,246	For
Exchange Place Advisors Trust	27,546	For

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

7. Elect Director: Michael P. Miller

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 34,501,336WITHHELD: 546,199

Details: description as filed, official tally, votes by 55 asset managers

Description as filed by funds: Election of directors to serve for a one-year term: Michael P. Miller

PUMA BIOTECHNOLOGY INC.’s own tally for this item (“Elect Director: Michael P. Miller”): 34,501,336 for, 546,199 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 55 asset managers below reported 10,112,240 for, 14,244 withheld, 105,823 abstained.

FOR

FOR: 10,112,240ABSTAIN: 105,823WITHHOLD: 14,244

Largest asset managers voting on “Election of directors to serve for a one-year term: Michael P. Miller” at PUMA BIOTECHNOLOGY INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	3,722,520	0	For
BlackRock	1,813,759	0	For
American Century	1,176,354	0	For
Fidelity	1,059,127	0	For
Dimensional	410,482	0	For
SEI	328,839	0	For
TARGET PORTFOLIO TRUST	276,200	0	For
Federated Hermes	193,766	0	For
BRIDGEWAY FUNDS INC	141,300	0	For
Charles Schwab	127,312	0	For
WisdomTree	83,143	0	For
Equitable	81,633	0	For
RBC FUNDS TRUST	0	71,800	Abstain
QUANTITATIVE MASTER SERIES LLC	67,080	0	For
Delaware/Macquarie	61,255	0	For
TIAA	55,922	0	For
GPS Funds I	43,280	0	For
Virtus	41,614	0	For
Goldman Sachs	40,114	0	For
Pacific Life	35,848	0	For
EA Series Trust	0	34,023	Abstain
Lincoln Financial	32,878	0	For
Legg Mason	32,690	0	For
Putnam	31,246	0	For
Exchange Place Advisors Trust	27,546	0	For

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

8. Elect Director: Troy E. Wilson

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

69% Majority: yes · of votes cast

FOR 69%WITHHELD

FOR: 24,308,330WITHHELD: 10,739,205

Details: description as filed, official tally, votes by 55 asset managers

Description as filed by funds: Election of directors to serve for a one-year term: Troy E. Wilson

PUMA BIOTECHNOLOGY INC.’s own tally for this item (“Elect Director: Troy E. Wilson”): 24,308,330 for, 10,739,205 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 69% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 3,359,977 for, 4,855,816 withheld, 2,016,514 abstained.

FORABSTAINWITHHOLD

FOR: 3,359,977ABSTAIN: 2,016,514WITHHOLD: 4,855,816

Largest asset managers voting on “Election of directors to serve for a one-year term: Troy E. Wilson” at PUMA BIOTECHNOLOGY INC., 2024-2025
Asset manager	For	Abstain	Withheld	Vote
Vanguard	86,986	0	3,635,534	Withhold
BlackRock	0	1,813,759	0	Abstain
American Century	1,176,354	0	0	For
Fidelity	1,059,127	0	0	For
Dimensional	410,482	0	0	For
SEI	0	0	328,839	Withhold
TARGET PORTFOLIO TRUST	0	0	276,200	Withhold
Federated Hermes	0	0	193,766	Withhold
BRIDGEWAY FUNDS INC	141,300	0	0	For
Charles Schwab	0	0	127,312	Withhold
WisdomTree	83,143	0	0	For
Equitable	0	0	81,633	Withhold
RBC FUNDS TRUST	0	71,800	0	Abstain
QUANTITATIVE MASTER SERIES LLC	0	67,080	0	Abstain
Delaware/Macquarie	0	0	61,255	Withhold
TIAA	55,922	0	0	For
GPS Funds I	43,280	0	0	For
Virtus	41,614	0	0	For
Goldman Sachs	40,114	0	0	For
Pacific Life	15,714	0	20,134	Mixed
EA Series Trust	0	34,023	0	Abstain
Lincoln Financial	3,378	0	29,500	Mixed
Legg Mason	32,690	0	0	For
Putnam	31,246	0	0	For
Exchange Place Advisors Trust	27,546	0	0	For

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

9. Proposal 3: The Company's stockholders voted to approve, on an advisory basis, the compensation of the Company's named…

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

95% Approved · of votes cast

FOR 95%

FOR: 32,617,895AGAINST: 1,698,665

Details: description as filed, official tally, votes by 148 asset managers

Description as filed by funds: ADVISORY (NON-BINDING) VOTE TO APPROVE THE COMPENSATION OF PUMA BIOTECHNOLOGY, INC.'S NAMED EXECUTIVE OFFICERS AS DESCRIBED IN THE PROXY STATEMENT.

PUMA BIOTECHNOLOGY INC.’s own tally for this item (“Proposal 3: The Company's stockholders voted to approve, on an advisory basis, the compensation of the Company's named executive officers.”): 32,617,895 for, 1,698,665 against — passed, per its Form 8-K filed June 13, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: The Company's stockholders voted to approve, on an advisory basis, the compensation of the Company's named executive officers.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 56 asset managers voting on “ADVISORY (NON-BINDING) VOTE TO APPROVE THE COMPENSATION OF PUMA BIOTECHNOLOGY, INC.'S NAMED EXECUTIVE OFFICERS” at PUMA BIOTECHNOLOGY INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	3,722,520	0	For
BlackRock	1,813,759	0	For
American Century	1,176,354	0	For
Fidelity	1,059,127	0	For
Dimensional	0	410,482	Against
SEI	328,839	0	For
TARGET PORTFOLIO TRUST	276,200	0	For
Federated Hermes	193,766	0	For
BRIDGEWAY FUNDS INC	0	141,300	Against
Charles Schwab	127,312	0	For
WisdomTree	83,143	0	For
Equitable	81,633	0	For
RBC FUNDS TRUST	71,800	0	For
QUANTITATIVE MASTER SERIES LLC	67,080	0	For
Delaware/Macquarie	61,255	0	For
TIAA	55,922	0	For
GPS Funds I	43,280	0	For
Virtus	41,614	0	For
Goldman Sachs	40,114	0	For
Pacific Life	35,848	0	For
EA Series Trust	34,023	0	For
Lincoln Financial	29,500	3,378	Mixed
Legg Mason	32,690	0	For
Putnam	31,246	0	For
Exchange Place Advisors Trust	27,546	0	For

Fund voting reports, all 56 managers: 9,648,871 for, 576,827 against, 10,018 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 111 asset managers voting on “ADVISORY (NON-BINDING) VOTE TO APPROVE THE COMPENSATION OF PUMA BIOTECHNOLOGY, INC.'S NAMED EXECUTIVE OFFICERS” at PUMA BIOTECHNOLOGY INC., 2024-2025
Asset manager	For	Against	Vote
BlackRock	1,491,877	0	For
American Century	1,199,517	0	For
GEODE CAPITAL MANAGEMENT, LLC	967,097	0	For
Renaissance	810,228	0	For
KENNEDY CAPITAL MANAGEMENT LLC	638,594	96,405	Mixed
State Street	595,819	2,376	For
DE Shaw	513,242	0	For
GLOBEFLEX CAPITAL L P	390,272	0	For
SEI	336,396	0	For
Connor, Clark & Lunn Investment Management Ltd.	295,497	0	For
Prudential/PGIM	289,835	0	For
Eversept Partners, LP	275,788	0	For
MARSHALL WACE, LLP	275,565	0	For
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	224,133	0	For
Two Sigma	222,285	0	For
Northern Trust	210,919	0	For
Federated Hermes	198,819	0	For
Newton Investment Management North America, LLC	160,800	0	For
MACKENZIE FINANCIAL CORP	157,713	0	For
O'SHAUGHNESSY ASSET MANAGEMENT, LLC	143,386	7,436	For
BRIDGEWAY CAPITAL MANAGEMENT, LLC	0	149,100	Against
STRS OHIO	141,900	0	For
MELLON INVESTMENTS Corp	137,882	0	For
Fidelity	128,443	0	For
Charles Schwab	127,319	0	For

Institutional-manager reports, all 111 managers: 10,863,475 for, 463,896 against, 120 abstained. Showing the 25 largest; see all in the interactive database.

10. 2. The selection of KPMG LLP as the Company's independent registered accounting firm for the fiscal year ending…

Official resultAUDIT-RELATEDReported outcome: Approved

98% Approved · of votes cast

FOR 98%

FOR: 40,683,257AGAINST: 739,693

Details: description as filed, official tally, votes by 56 asset managers

Description as filed by funds: RATIFICATION OF THE SELECTION OF KPMG LLP AS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF PUMA BIOTECHNOLOGY, INC. FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

PUMA BIOTECHNOLOGY INC.’s own tally for this item (“2. The selection of KPMG LLP as the Company's independent registered accounting firm for the fiscal year ending December 31, 2025”): 40,683,257 for, 739,693 against — passed, per its Form 8-K filed June 13, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: The Company's stockholders ratified the selection of KPMG LLP as the Company's independent registered accounting firm for the fiscal year ending December 31, 2025.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 10,046,149 for, 179,549 against, 10,018 abstained.

FOR

FOR: 10,046,149AGAINST: 179,549ABSTAIN: 10,018

Largest asset managers voting on “RATIFICATION OF THE SELECTION OF KPMG LLP AS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF PUMA BIOTECHNOLO” at PUMA BIOTECHNOLOGY INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	3,722,520	0	For
BlackRock	1,813,759	0	For
American Century	1,176,354	0	For
Fidelity	1,059,127	0	For
Dimensional	410,482	0	For
SEI	328,839	0	For
TARGET PORTFOLIO TRUST	276,200	0	For
Federated Hermes	193,766	0	For
BRIDGEWAY FUNDS INC	0	141,300	Against
Charles Schwab	127,312	0	For
WisdomTree	83,143	0	For
Equitable	81,633	0	For
RBC FUNDS TRUST	71,800	0	For
QUANTITATIVE MASTER SERIES LLC	67,080	0	For
Delaware/Macquarie	61,255	0	For
TIAA	55,922	0	For
GPS Funds I	43,280	0	For
Virtus	41,614	0	For
Goldman Sachs	40,114	0	For
Pacific Life	35,848	0	For
EA Series Trust	0	34,023	Against
Lincoln Financial	32,878	0	For
Legg Mason	32,690	0	For
Putnam	31,246	0	For
Exchange Place Advisors Trust	27,546	0	For

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

Largest PUMA BIOTECHNOLOGY INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 49,638,093 shares outstanding at the time of that meeting.

Fund voting reports: top PUMA BIOTECHNOLOGY INC. shareholders by shares voted on “ADVISORY (NON-BINDING) VOTE TO APPROVE THE COMPENSATION OF PUMA BIOTECHNOLOGY, INC.'S NAMED…”, 2024-2025
#	Asset manager	% of shares outstanding
1	Vanguard	7.50%
2	BlackRock	3.65%
3	American Century	2.37%
4	Fidelity	2.13%
5	Dimensional	0.83%
6	SEI	0.66%
7	TARGET PORTFOLIO TRUST	0.56%
8	Federated Hermes	0.39%
9	BRIDGEWAY FUNDS INC	0.28%
10	Charles Schwab	0.26%

Institutional-manager reports: top PUMA BIOTECHNOLOGY INC. shareholders by shares voted on “ADVISORY (NON-BINDING) VOTE TO APPROVE THE COMPENSATION OF PUMA BIOTECHNOLOGY, INC.'S NAMED…”, 2024-2025
#	Asset manager	% of shares outstanding
1	BlackRock	3.01%
2	American Century	2.42%
3	GEODE CAPITAL MANAGEMENT, LLC	1.95%
4	Renaissance	1.63%
5	KENNEDY CAPITAL MANAGEMENT LLC	1.48%
6	State Street	1.21%
7	DE Shaw	1.03%
8	GLOBEFLEX CAPITAL L P	0.79%
9	SEI	0.68%
10	Connor, Clark & Lunn Investment Management Ltd.	0.60%

Reported PUMA BIOTECHNOLOGY INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

PUMA BIOTECHNOLOGY INC. holdings and ownership disclosed for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Anders Hove	7.94%	13G
BlackRock	7.75%	13F
Vanguard Group	7.39%	13F
Renaissance Technologies	3.69%	13F
Millennium Management	2.79%	13F
Geode Capital	1.92%	13F
Dimensional Fund Advisors	1.79%	13F
State Street	1.31%	13F
D.E. Shaw	1.15%	13F
BNY Mellon	0.69%	13F

Percentages above are of 49,638,093 shares outstanding, as reported by PUMA BIOTECHNOLOGY INC. on its Form 10-Q dated May 5, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from PUMA BIOTECHNOLOGY INC.’s 10-Q dated May 5, 2025. This page is a static snapshot rebuilt weekly on October 25, 2026; a live search always shows the current data.

At PUMA BIOTECHNOLOGY INC.'s shareholder meeting held June 11, 2025, in the 2024-2025 proxy season, 148 asset managers reported how they voted on 10 ballot items in their SEC Form N-PX filings, covering 1,532 separate fund positions. On the most widely held item on that ballot — ADVISORY (NON-BINDING) VOTE TO APPROVE THE COMPENSATION OF PUMA BIOTECHNOLOGY, INC.'S NAMED… — PUMA BIOTECHNOLOGY INC.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: PUMA BIOTECHNOLOGY INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 13, 2025.

PUMA BIOTECHNOLOGY INC. proxy season coverage: 2024-2025 (this page) · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.